SignalSilence® ERCC1 siRNA IProduct information
|300 µl (3 nmol)||-||Unavailable in your region|
Product Pathways - DNA Damage
SignalSilence® ERCC1 siRNA I #8896
|8896S||300 µl (3 nmol)||---||In Stock||---|
|8896||carrier free and custom formulation / quantity||email request|
Product is assembled upon order. Please allow up to 1 week for your product to be processed.
Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-) or SignalSilence® ERCC1 siRNA I (+), using ERCC1 (D61F5) Rabbit mAb #5437 (upper) or β-Actin (D6A8) Rabbit mAb #8457 (lower). The ERCC1 (D61F5) Rabbit mAb confirms silencing of ERCC1 expression while the β-Actin (D6A8) Rabbit mAb is used as a loading control.
SignalSilence® ERCC1 siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit ERCC1 expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce protein expression by western analysis.
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions For Use
CST recommends transfection with 100 nM SignalSilence® ERCC1 siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.
DNA repair systems operate in all living cells to manage a variety of DNA lesions. Nucleotide excision repair (NER) is implemented in cases where bulky helix-distorting lesions occur, such as those brought about by UV and certain chemicals (1). Excision Repair Cross Complementing 1 (ERCC1) forms a complex with ERCC4/XPF, which acts as the 5’ endonuclease required to excise the lesion (2). ERCC1-XPF is also required for repair of DNA interstrand crosslinks (ICLs) (3) and involved in repair of double strand breaks (4). Research studies have shown that expression of ERCC1 is related to survival rate and response to chemotherapeutic drugs in several human cancers including non-small cell lung cancer (NSCLC) (5,6).
- Shuck, S.C. et al. (2008) Cell Res 18, 64-72.
- McDaniel, L.D. and Schultz, R.A. (2008) Adv Exp Med Biol 637, 65-82.
- Niedernhofer, L.J. et al. (2004) Mol Cell Biol 24, 5776-87.
- Ahmad, A. et al. (2008) Mol Cell Biol 28, 5082-92.
- Zheng, Z. et al. (2007) N Engl J Med 356, 800-8.
- Gossage, L. and Madhusudan, S. (2007) Cancer Treat Rev 33, 565-77.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
SignalSilence is a registered trademark of Cell Signaling Technology, Inc.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.